Relatively-subdued COVID-19 fears
23/03/20 -"With aggravating COVID-19 fears and a material effect on the pharma supply chain – especially with respect to APIs, other than already known biosimilar risks, near-term earnings pressure is ..."
Pages
71
Language
English
Published on
23/03/20
You may also be interested by these reports :
17/07/25
The Q2 sales growth, despite being impacted by adverse FX movements, impressed the markets. Both the segments contributed healthily to the quarterly ...
17/07/25
Q2 results were somewhat ahead of expectations, supported by healthy momentum across focus areas. Management also raised its full-year profitability ...
14/07/25
We have refined our estimates for the forecasting period by removing the €100m financing measure and the associated issuance of approximately 14 ...
14/07/25
BioNTech’s acquisition of CureVac was a strategic move. This decision resolves potential costly issues, including the patent dispute with CureVac, ...